Evidence map›Paper›PMID 33693799›Full record

ArticleJournal of the National Cancer Institute2021

Sleep Disruption, Fatigue, and Depression as Predictors of 6-Year Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation.

Kelly E Rentscher, Judith E Carroll, Mark B Juckett, Christopher L Coe, Aimee T Broman, Paul J Rathouz, Peiman Hematti, Erin S Costanzo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kelly E RentscherDepartment of Psychiatry and Biobehavioral Sciences, Cousins Center for Psychoneuroimmunology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.ORCID 0000-0003-1887-3953
Judith E CarrollDepartment of Psychiatry and Biobehavioral Sciences, Cousins Center for Psychoneuroimmunology, Jane and Terry Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.ORCID 0000-0001-5516-0819
Mark B JuckettDepartment of Medicine, Division of Hematology/Oncology, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0003-2074-5678
Christopher L CoeDepartment of Psychology, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0001-9335-9060
Aimee T BromanDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0003-3783-2807
Paul J RathouzDepartment of Population Health, University of Texas at Austin, Austin, TX, USA.
Peiman HemattiDepartment of Medicine, Division of Hematology/Oncology, University of Wisconsin-Madison, Madison, WI, USA.
Erin S CostanzoCarbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
University of Wisconsin–Madison · USUniversity of California, Los Angeles · USThe University of Texas at Austin · US

Funding

Biobehavioral Mechanisms Facilitating Recovery From Stem Cell TransplantationK07CA136966 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI COSTANZO, ERIN · 2011 to 2015
$744k
Accelerated biological and phenotypic aging in hematopoietic cell transplant survivors: Social support as a protective factorK01AG065485 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RENTSCHER, KELLY E · 2020 to 2024
$600k
Predictors of Optimal Immune Reconstitution in Stem Cell Transplant PatientsR21CA133343 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI COSTANZO, ERIN · 2010 to 2011
$350k
NCI NIH HHS K07 CA136966NCI NIH HHS R21 CA133343NIA NIH HHS K01 AG065485
6 · The paper itself

Abstract

backgroundAllogeneic hematopoietic cell transplantation (HCT) is a widely used treatment for hematologic cancers, with survival rates ranging from 25% to 78%. Known risk factors for chronic graft-versus-host disease (cGVHD), a serious and common long-term complication, disease relapse, and mortality following HCT have been identified, but much of the variability in HCT outcomes is unexplained. Biobehavioral symptoms including depression, sleep disruption, and fatigue are some of the most prevalent and distressing for patients; yet research on biobehavioral risk factors for HCT outcomes is limited. This study evaluated patient-reported depression, sleep disruption, and fatigue as risk factors for cGVHD, disease relapse, and mortality.

methodsAdults receiving allogeneic HCT for a hematologic malignancy (N = 241) completed self-report measures of depression symptoms, sleep quality, and fatigue (severity, interference) pre-HCT and 100 days post-HCT. Clinical outcomes were monitored for up to 6 years.

resultsCox proportional hazard models (2-tailed) adjusting for patient demographic and medical characteristics revealed that high pre-HCT sleep disruption (Pittsburgh Sleep Quality Index >9; hazard ratio [HR] = 2.74, 95% confidence interval [CI] = 1.27 to 5.92) and greater post-HCT fatigue interference (HR = 1.32, 95% CI = 1.05 to 1.66) uniquely predicted increased risk of mortality. Moderate pre-HCT sleep disruption (Pittsburgh Sleep Quality Index 6-9) predicted increased risk of relapse (HR = 1.99, 95% CI = 1.02 to 3.87). Biobehavioral symptoms did not predict cGVHD incidence.

conclusionsBiobehavioral symptoms, particularly sleep disruption and fatigue interference, predicted an increased risk for 6-year relapse and mortality after HCT. Because these symptoms are amenable to treatment, they offer specific targets for intervention to improve HCT outcomes.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationDepressionFatigueHumansNeoplasm Recurrence, LocalSleep

Identifiers

PMID33693799
PMCPMC8633423
OpenAlexW3134756697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.